BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
Vikas A Gupta,1 James Ackley,2 Jonathan L Kaufman,1 Lawrence H Boise1 1Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA; 2Cancer Biology Graduate Program, Winship Cancer Institute of Emory University, E...
Saved in:
Main Authors: | Gupta VA, Ackley J, Kaufman JL, Boise LH |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/e6d2cffa79a14fa8a38bd9e29bf1c781 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
by: Gupta VA, et al.
Published: (2013) -
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
by: Schieber M, et al.
Published: (2019) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
by: Angelo Maiolino, et al.
Published: (2021) -
Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
by: Faiman B, et al.
Published: (2016)